Waltham, MA, March 2, 2020 – Trinity Life Sciences, a global leader in life sciences solutions, today announced it continues to see inflective growth in its Health Economics and Outcomes Research (HEOR) services.
HEOR, one of the fastest-growing functions in the pharmaceutical industry, provides value-based insight to pharmaceutical companies and assists healthcare payers in determining if treatments are effective in the populations they serve.
“HEOR plays a central role in the internal decision-making of a pharmaceutical or biotech company,” said David Fitzhenry, CEO, Trinity. “While it has always been an important function, we’ve noticed a real upswing in recent years, with HEOR work being pivotal in telling the value story for the product or treatment and helping drive in-market success for our clients. We’ve had the privilege to work with some really terrific clients, in some challenging therapeutic areas, but frankly the team loves that.”
Trinity offers a wide range of HEOR offerings, from developing evidence generation plans, to executing RWE studies, to scientific communication through Posters and Manuscripts.
“Understanding the competitive landscape and the specific
evidentiary needs of stakeholders in a therapy area is critical to develop the
most optimal evidence generation plans (EGPs) for our clients,” said Nandini Hadker,
Partner, Head of HEOR at Trinity. “Then, depending on the true needs in the
marketplace, the EGP might involve a wide range of study types targeting specific
stakeholder audiences: burden of illness, RWE/claims, primary RWE studies using
choice/trade-off exercises or medical chart audits, HECON modeling, literature reviews,
etc. We thrive on helping our clients develop the most compelling evidentiary
package to drive market shaping activities, medical education and market access
for their products.”
Expanding the Team
In response to the growth in and demand for HEOR-related programs and services, Trinity has on-boarded two new senior members to its HEOR division:
For an example of the HEOR team’s work, using medical chart audits to assess real world treatment patterns, visit: Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors—A retrospective analysis.
Note: this was the most downloaded article in Haemophilia in 2018.
About Trinity Life Sciences Trinity Life Sciences is a trusted strategic partner, providing evidence-based solutions for the life sciences. With over 20 years of experience, Trinity is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools, and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity is elevating life sciences and driving evidence to action, visit trinitylifesciences.com.
For more information:
Trinity Life Sciences